Nasus Pharma is trading at $3.59, up 10.80%, with no specific cause identified for its October 21 move.
- No new company-specific catalyst explaining the move surfaced; the latest identified company announcement was September 29, about starting a Phase 1 study of NS003.
- Healthcare was reported up 2.12% in the regular session, providing positive sector context but not establishing the reason for the larger move.